시장보고서
상품코드
1459781

바이오마커 시장 : 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2023-2031년)

Biomarkers Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

발행일: | 리서치사: Transparency Market Research | 페이지 정보: 영문 201 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

바이오마커 시장 - 조사범위

TMR의 세계 바이오마커 시장 조사 보고서는 2023년부터 2031년까지의 예측 기간 동안 시장 지표에 대한 귀중한 통찰력을 얻기 위해 과거뿐만 아니라 현재의 성장 동향과 기회를 조사했습니다. 이 보고서는 2023년을 기준 연도, 2031년을 예측 연도로 하여 2017년부터 2031년까지 세계 바이오마커 시장의 수익을 제공합니다. 또한 2023년부터 2031년까지 세계 바이오마커 시장의 연평균 성장률(CAGR%)도 제시합니다.

이 보고서는 1차 조사에서 KOL(Key Opinion Leader), 업계 리더, 오피니언 제조업체를 인터뷰하고, 2차 조사에서 주요 기업의 제품 자료, 연례 보고서, 보도 자료, 관련 문서를 검토하여 바이오마커 시장을 이해하고자 했습니다. 참고하였습니다.

시장 현황
2022년 시장 규모 512억 달러
2031년 시장 가치 1,256억 달러
CAGR 10.4%

이 보고서는 세계 바이오마커 시장 경쟁 구도를 심층적으로 분석합니다. 세계 바이오마커 시장에서 사업을 전개하고 있는 주요 기업들이 확인되었으며, 각 기업들은 다양한 속성으로 프로파일링되었습니다. 기업 개요, 재무 상태, 최근 시장 개척, SWOT는 이 보고서에서 소개되는 세계 바이오마커 시장의 기업 속성입니다.

목차

제1장 서문

제2장 조사의 전제조건과 조사 방법

제3장 주요 요약 : 세계 시장

제4장 시장 개요

  • 서론
  • 시장 개요
  • 시장 역학
  • 세계 시장 분석과 예측, 2017년-2031년

제5장 키 통찰

  • 기술 진보
  • 세계 질환 유병률과 이환율, 주요 국가별
  • 지역별/세계 전체 규제 시나리오
  • COVID-19의 영향 분석

제6장 세계 시장 분석과 예측 : 제품 및 서비스별

  • 서론과 정의
  • 주요 조사 결과/발전
  • 시장 매출 예측 : 제품 및 서비스별, 2017년-2031년
    • 소모품
    • 서비스
    • 기기
  • 제품 및 서비스별 시장의 매력

제7장 세계 시장 분석과 예측 : 적응 질환별

  • 서론과 정의
  • 주요 조사 결과/발전
  • 용도별 시장 매출 예측, 2017년-2031년
    • 진단약
    • Drug Discovery&Development
    • 맞춤형 의료
    • 질병 리스크 평가
    • 기타
  • 용도별 시장의 매력

제8장 세계 시장 분석과 예측 : 유형별

  • 서론과 정의
  • 주요 조사 결과/발전
  • 유형별 시장 매출 예측, 2017년-2031년
    • 안전성
    • 감수성/리스크
    • 진단약
    • 예후
    • 모니터링
    • 예측
    • 약력학/반응
  • 유형별 시장의 매력

제9장 세계 시장 분석과 예측 : 적응 질환별

  • 서론과 정의
  • 주요 조사 결과/발전
  • 질환 적응증별 시장 매출 예측, 2017년-2031년
    • 신경 질환
    • 심혈관 질환
    • 감염증
    • 면역 질환
    • 기타
  • 적응 질환별 시장의 매력

제10장 세계 시장 분석과 예측 : 지역별

  • 주요 조사 결과
  • 지역별 시장 매출 예측
    • 북미
    • 유럽
    • 아시아태평양
    • 라틴아메리카
    • 중동 및 아프리카
  • 국가/지역별 시장의 매력

제11장 북미 시장 분석과 예측

  • 미국
  • 캐나다

제12장 유럽 시장 분석과 예측

  • 독일
  • 영국
  • 프랑스
  • 스페인
  • 이탈리아
  • 기타 유럽

제13장 아시아태평양 시장 분석과 예측

  • 중국
  • 일본
  • 인도
  • 호주 및 뉴질랜드
  • 기타 아시아태평양

제14장 라틴아메리카 시장 분석과 예측 라틴아메리카 시장 분석과 예측

  • 브라질
  • 멕시코
  • 기타 라틴아메리카

제15장 중동 및 아프리카 시장 분석과 예측

  • GCC 국가
  • 남아프리카공화국
  • 기타 중동 및 아프리카

제16장 경쟁 구도

  • 기업 점유율 분석(2022년)
  • 기업 개요
    • Abbott Laboratories
    • Agilent Technology
    • Becton, Dickinson and Company
    • Bio-Rad Laboratories
    • BioMerieux SA(Astute Medical)
    • Merck KGaA
    • Qiagen NV
    • Quanterix
    • Quest Diagnostics
    • Thermo Fisher Scientific Inc.
LSH 24.04.25

Biomarkers Market - Scope of Report

TMR's report on the global biomarkers market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global biomarkers market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global biomarkers market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the biomarkers market.

Market Snapshot
Market Value in 2022US$ 51.2 Bn
Market Value in 2031US$ 125.6 Bn
CAGR10.4%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global biomarkers market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global biomarkers market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global biomarkers market.

The report delves into the competitive landscape of the global biomarkers market. Key players operating in the global biomarkers market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global biomarkers market profiled in this report.

Key Questions Answered in Global biomarkers Market Report:

  • What is the sales/revenue generated by biomarkers across all regions during the forecast period?
  • What are the opportunities in the global biomarkers market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Biomarkers Market - Research Objectives and Research Approach

The comprehensive report on the global biomarkers market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global biomarkers market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global biomarkers market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Biomarkers Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Biomarkers Market Analysis and Forecasts, 2017-2031

5. Key Insights

  • 5.1. Technological Advancements
  • 5.2. Disease Prevalence & Incidence Rate Globally with Key Countries
  • 5.3. Regulatory Scenario by Region/globally
  • 5.4. COVID-19 Impact Analysis

6. Global Biomarkers Market Analysis and Forecasts, By Product & Service

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast By Product & Service, 2017-2031
    • 6.3.1. Consumables
    • 6.3.2. Services
    • 6.3.3. Equipment
  • 6.4. Market Attractiveness By Product & Service

7. Global Biomarkers Market Analysis and Forecasts, By Disease Indication

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast By Application, 2017-2031
    • 7.3.1. Diagnostics
    • 7.3.2. Drug Discovery & Development
    • 7.3.3. Personalized Medicine
    • 7.3.4. Disease Risk Assessment
    • 7.3.5. Others
  • 7.4. Market Attractiveness By Application

8. Global Biomarkers Market Analysis and Forecasts, By Type

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast By Type, 2017-2031
    • 8.3.1. Safety Biomarkers
    • 8.3.2. Susceptibility/Risk Biomarkers
    • 8.3.3. Diagnostic Biomarkers
    • 8.3.4. Prognostic Biomarkers
    • 8.3.5. Monitoring Biomarkers
    • 8.3.6. Predictive Biomarkers
    • 8.3.7. Pharmacodynamic/Response Biomarkers
  • 8.4. Market Attractiveness By Type

9. Global Biomarkers Market Analysis and Forecasts, By Disease Indication

  • 9.1. Introduction & Definition
  • 9.2. Key Findings / Developments
  • 9.3. Market Value Forecast By Disease Indication, 2017-2031
    • 9.3.1. Cancer
    • 9.3.2. Neurological Disorders
    • 9.3.3. Cardiovascular Disorders
    • 9.3.4. Infectious Diseases
    • 9.3.5. Immune Disorders
    • 9.3.6. Others
  • 9.4. Market Attractiveness By Disease Indication

10. Global Biomarkers Market Analysis and Forecasts, By Region

  • 10.1. Key Findings
  • 10.2. Market Value Forecast By Region
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Market Attractiveness By Country/Region

11. North America Biomarkers Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast By Product & Service, 2017-2031
    • 11.2.1. Consumables
    • 11.2.2. Services
    • 11.2.3. Equipment
  • 11.3. Market Value Forecast By Application, 2017-2031
    • 11.3.1. Diagnostics
    • 11.3.2. Drug Discovery & Development
    • 11.3.3. Personalized Medicine
    • 11.3.4. Disease Risk Assessment
    • 11.3.5. Others
  • 11.4. Market Value Forecast By Type, 2017-2031
    • 11.4.1. Safety Biomarkers
    • 11.4.2. Susceptibility/Risk Biomarkers
    • 11.4.3. Diagnostic Biomarkers
    • 11.4.4. Prognostic Biomarkers
    • 11.4.5. Monitoring Biomarkers
    • 11.4.6. Predictive Biomarkers
    • 11.4.7. Pharmacodynamic/Response Biomarkers
  • 11.5. Market Value Forecast By Disease Indication, 2017-2031
    • 11.5.1. Cancer
    • 11.5.2. Neurological Disorders
    • 11.5.3. Cardiovascular Disorders
    • 11.5.4. Infectious Diseases
    • 11.5.5. Immune Disorders
    • 11.5.6. Others
  • 11.6. Market Value Forecast By Country, 2017-2031
    • 11.6.1. U.S.
    • 11.6.2. Canada
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Product & Service
    • 11.7.2. By Application
    • 11.7.3. By Type
    • 11.7.4. By Disease Indication
    • 11.7.5. By Country

12. Europe Biomarkers Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast By Product & Service, 2017-2031
    • 12.2.1. Consumables
    • 12.2.2. Services
    • 12.2.3. Equipment
  • 12.3. Market Value Forecast By Application, 2017-2031
    • 12.3.1. Diagnostics
    • 12.3.2. Drug Discovery & Development
    • 12.3.3. Personalized Medicine
    • 12.3.4. Disease Risk Assessment
    • 12.3.5. Others
  • 12.4. Market Value Forecast By Type, 2017-2031
    • 12.4.1. Safety Biomarkers
    • 12.4.2. Susceptibility/Risk Biomarkers
    • 12.4.3. Diagnostic Biomarkers
    • 12.4.4. Prognostic Biomarkers
    • 12.4.5. Monitoring Biomarkers
    • 12.4.6. Predictive Biomarkers
    • 12.4.7. Pharmacodynamic/Response Biomarkers
  • 12.5. Market Value Forecast By Disease Indication, 2017-2031
    • 12.5.1. Cancer
    • 12.5.2. Neurological Disorders
    • 12.5.3. Cardiovascular Disorders
    • 12.5.4. Infectious Diseases
    • 12.5.5. Immune Disorders
    • 12.5.6. Others
  • 12.6. Market Value Forecast By Country/Sub-region, 2017-2031
    • 12.6.1. Germany
    • 12.6.2. U.K.
    • 12.6.3. France
    • 12.6.4. Spain
    • 12.6.5. Italy
    • 12.6.6. Rest of Europe
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Product & Service
    • 12.7.2. By Application
    • 12.7.3. By Type
    • 12.7.4. By Disease Indication
    • 12.7.5. By Country/Sub-region

13. Asia Pacific Biomarkers Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast By Product & Service, 2017-2031
    • 13.2.1. Consumables
    • 13.2.2. Services
    • 13.2.3. Equipment
  • 13.3. Market Value Forecast By Application, 2017-2031
    • 13.3.1. Diagnostics
    • 13.3.2. Drug Discovery & Development
    • 13.3.3. Personalized Medicine
    • 13.3.4. Disease Risk Assessment
    • 13.3.5. Others
  • 13.4. Market Value Forecast By Type, 2017-2031
    • 13.4.1. Safety Biomarkers
    • 13.4.2. Susceptibility/Risk Biomarkers
    • 13.4.3. Diagnostic Biomarkers
    • 13.4.4. Prognostic Biomarkers
    • 13.4.5. Monitoring Biomarkers
    • 13.4.6. Predictive Biomarkers
    • 13.4.7. Pharmacodynamic/Response Biomarkers
  • 13.5. Market Value Forecast By Disease Indication, 2017-2031
    • 13.5.1. Cancer
    • 13.5.2. Neurological Disorders
    • 13.5.3. Cardiovascular Disorders
    • 13.5.4. Infectious Diseases
    • 13.5.5. Immune Disorders
    • 13.5.6. Others
  • 13.6. Market Value Forecast By Country/Sub-region, 2017-2031
    • 13.6.1. China
    • 13.6.2. Japan
    • 13.6.3. India
    • 13.6.4. Australia & New Zealand
    • 13.6.5. Rest of Asia Pacific
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Product & Service
    • 13.7.2. By Application
    • 13.7.3. By Type
    • 13.7.4. By Disease Indication
    • 13.7.5. By Country/Sub-region

14. Latin America Biomarkers Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast By Product & Service, 2017-2031
    • 14.2.1. Consumables
    • 14.2.2. Services
    • 14.2.3. Equipment
  • 14.3. Market Value Forecast By Application, 2017-2031
    • 14.3.1. Diagnostics
    • 14.3.2. Drug Discovery & Development
    • 14.3.3. Personalized Medicine
    • 14.3.4. Disease Risk Assessment
    • 14.3.5. Others
  • 14.4. Market Value Forecast By Type, 2017-2031
    • 14.4.1. Safety Biomarkers
    • 14.4.2. Susceptibility/Risk Biomarkers
    • 14.4.3. Diagnostic Biomarkers
    • 14.4.4. Prognostic Biomarkers
    • 14.4.5. Monitoring Biomarkers
    • 14.4.6. Predictive Biomarkers
    • 14.4.7. Pharmacodynamic/Response Biomarkers
  • 14.5. Market Value Forecast By Disease Indication, 2017-2031
    • 14.5.1. Cancer
    • 14.5.2. Neurological Disorders
    • 14.5.3. Cardiovascular Disorders
    • 14.5.4. Infectious Diseases
    • 14.5.5. Immune Disorders
    • 14.5.6. Others
  • 14.6. Market Value Forecast By Country/Sub-region, 2017-2031
    • 14.6.1. Brazil
    • 14.6.2. Mexico
    • 14.6.3. Rest of Latin America
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Product & Service
    • 14.7.2. By Application
    • 14.7.3. By Type
    • 14.7.4. By Disease Indication
    • 14.7.5. By Country/Sub-region

15. Middle East & Africa Biomarkers Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast By Product & Service, 2017-2031
    • 15.2.1. Consumables
    • 15.2.2. Services
    • 15.2.3. Equipment
  • 15.3. Market Value Forecast By Application, 2017-2031
    • 15.3.1. Diagnostics
    • 15.3.2. Drug Discovery & Development
    • 15.3.3. Personalized Medicine
    • 15.3.4. Disease Risk Assessment
    • 15.3.5. Others
  • 15.4. Market Value Forecast By Type, 2017-2031
    • 15.4.1. Safety Biomarkers
    • 15.4.2. Susceptibility/Risk Biomarkers
    • 15.4.3. Diagnostic Biomarkers
    • 15.4.4. Prognostic Biomarkers
    • 15.4.5. Monitoring Biomarkers
    • 15.4.6. Predictive Biomarkers
    • 15.4.7. Pharmacodynamic/Response Biomarkers
  • 15.5. Market Value Forecast By Disease Indication, 2017-2031
    • 15.5.1. Cancer
    • 15.5.2. Neurological Disorders
    • 15.5.3. Cardiovascular Disorders
    • 15.5.4. Infectious Diseases
    • 15.5.5. Immune Disorders
    • 15.5.6. Others
  • 15.6. Market Value Forecast By Country/Sub-region, 2017-2031
    • 15.6.1. GCC Countries
    • 15.6.2. South Africa
    • 15.6.3. Rest of Middle East & Africa
  • 15.7. Market Attractiveness Analysis
    • 15.7.1. By Product & Service
    • 15.7.2. By Application
    • 15.7.3. By Type
    • 15.7.4. By Disease Indication
    • 15.7.5. By Country/Sub-region

16. Competition Landscape

  • 16.1. Market Share Analysis By Company (2022)
  • 16.2. Company Profiles
    • 16.2.1. Abbott Laboratories
      • 16.2.1.1. Company Overview
      • 16.2.1.2. Financial Overview
      • 16.2.1.3. Product Portfolio
      • 16.2.1.4. Business Strategies
      • 16.2.1.5. Recent Developments
    • 16.2.2. Agilent Technology
      • 16.2.2.1. Company Overview
      • 16.2.2.2. Financial Overview
      • 16.2.2.3. Product Portfolio
      • 16.2.2.4. Business Strategies
      • 16.2.2.5. Recent Developments
    • 16.2.3. Becton, Dickinson and Company
      • 16.2.3.1. Company Overview
      • 16.2.3.2. Financial Overview
      • 16.2.3.3. Product Portfolio
      • 16.2.3.4. Business Strategies
      • 16.2.3.5. Recent Developments
    • 16.2.4. Bio-Rad Laboratories
      • 16.2.4.1. Company Overview
      • 16.2.4.2. Financial Overview
      • 16.2.4.3. Product Portfolio
      • 16.2.4.4. Business Strategies
      • 16.2.4.5. Recent Developments
    • 16.2.5. BioMerieux SA (Astute Medical)
      • 16.2.5.1. Company Overview
      • 16.2.5.2. Financial Overview
      • 16.2.5.3. Product Portfolio
      • 16.2.5.4. Business Strategies
      • 16.2.5.5. Recent Developments
    • 16.2.6. Merck KGaA
      • 16.2.6.1. Company Overview
      • 16.2.6.2. Financial Overview
      • 16.2.6.3. Product Portfolio
      • 16.2.6.4. Business Strategies
      • 16.2.6.5. Recent Developments
    • 16.2.7. Qiagen NV
      • 16.2.7.1. Company Overview
      • 16.2.7.2. Financial Overview
      • 16.2.7.3. Product Portfolio
      • 16.2.7.4. Business Strategies
      • 16.2.7.5. Recent Developments
    • 16.2.8. Quanterix
      • 16.2.8.1. Company Overview
      • 16.2.8.2. Financial Overview
      • 16.2.8.3. Product Portfolio
      • 16.2.8.4. Business Strategies
      • 16.2.8.5. Recent Developments
    • 16.2.9. Quest Diagnostics
      • 16.2.9.1. Company Overview
      • 16.2.9.2. Financial Overview
      • 16.2.9.3. Product Portfolio
      • 16.2.9.4. Business Strategies
      • 16.2.9.5. Recent Developments
    • 16.2.10. Thermo Fisher Scientific Inc.
      • 16.2.10.1. Company Overview
      • 16.2.10.2. Financial Overview
      • 16.2.10.3. Product Portfolio
      • 16.2.10.4. Business Strategies
      • 16.2.10.5. Recent Developments
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제